On this page
Novoeight
Antihemophilic Factor (Recombinant)
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Novoeight
Proper name
Antihemophilic Factor (Recombinant)
Licence type
351(a)
BLA number
125466
Applicant
Novo Nordisk Inc.
Center
CBER
Presentations
6
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 1000IU | For Injection | Intravenous | Single-Dose Vial | Rx | October 15, 2013 |
| 1500IU | For Injection | Intravenous | Single-Dose Vial | Rx | October 15, 2013 |
| 2000IU | For Injection | Intravenous | Single-Dose Vial | Rx | October 15, 2013 |
| 250IU | For Injection | Intravenous | Single-Dose Vial | Rx | October 15, 2013 |
| 3000IU | For Injection | Intravenous | Single-Dose Vial | Rx | October 15, 2013 |
| 500IU | For Injection | Intravenous | Single-Dose Vial | Rx | October 15, 2013 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |